Industry news that matters to you.  Learn more

Quest Diagnostics to Acquire Cleveland HeartLab and Form Strategic Collaboration with Cleveland Clinic

Quest Diagnostics (NYSE: DGX) today announced it has formed a definitive agreement to acquire Cleveland HeartLab, a leader in innovative diagnostic services for managing cardiovascular disease, from equity investors, including Cleveland Clinic. Quest intends to establish a national center of excellence in diagnostic information services at Cleveland HeartLab’s specialized laboratory in Cleveland, Ohio, focused on services that aid in assessing risk and treatment protocols for heart disease, the leading cause of death in the United States.

Boston Heart Enables Healthcare Providers to Better Identify Near-Term Risk of Heart Attack or Stroke with Launch of an Important Inflammation Marker, Myeloperoxidase (MPO)

Boston Heart Diagnostics Corporation, a pioneer in integrating next-generation diagnostics into personalized nutrition and lifestyle programs for patients with or at risk for heart disease, recently announced the commercial launch of an FDA-cleared MPO (myeloperoxidase) test, a key biomarker for inflammation. Studies show that MPO levels are useful predictors of near-term (one to six months) risk of heart attack or stroke.

Cardiac Diagnostics Company Unveils Invitation-Only Website For Key Opinion Leaders

Critical Diagnostics recently announced the launch of ST2online.com, a free online resource designed to deliver clinical and research information specific to ST2—a cardiac biomarker that, in over 100 clinical trials has shown to be the most prognostic biomarker for improving the management of heart failure.

One-Third Of Patients Who Receive Stents And Have Evidence Of Arterial Dysfunction At High Risk For Major Cardiovascular Events, Study Finds

Data from a new study indicate that the results of an FDA-approved test for endothelial (arterial) function significantly correlated with near-future cardiovascular events, including revascularization, chest pain, heart attack, heart failure, stroke and even death in high-risk patients, of which the majority have had stents implanted. Early diagnosis of near-future cardiovascular events is critical for the physicians who manage these high-risk patients. The study was published in the December issue of the Journal of the American Heart Association. The diagnostic device, the EndoPAT™, is manufactured by Itamar Medical (TASE:ITMR). 

Corgenix Announces Diagnostic Test Development Partnership with Health Diagnostic Laboratory, Inc.

Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, recently announced a strategic partnership with Health Diagnostic Laboratory, Inc. (HDL, Inc.) for the development of a clinical Laboratory Developed Test (LDT). The LDT would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.